<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Single nucleotide polymorphism arrays (SNP-As) have emerged as an important tool in the identification of chromosomal defects undetected by metaphase cytogenetics (MC) in <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic cancers</z:e>, offering superior resolution of unbalanced chromosomal defects and acquired copy-neutral loss of heterozygosity </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (MDSs) and related <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> share recurrent chromosomal defects and molecular lesions that predict outcomes </plain></SENT>
<SENT sid="2" pm="."><plain>We hypothesized that combining SNP-A and MC could improve diagnosis/prognosis and further the molecular characterization of <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>We analyzed MC/SNP-A results from 430 patients (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> = 250, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/myeloproliferative overlap <z:hpo ids='HP_0002664'>neoplasm</z:hpo> = 95, <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> = 85) </plain></SENT>
<SENT sid="4" pm="."><plain>The frequency and clinical significance of genomic aberrations was compared between MC and MC plus SNP-A </plain></SENT>
<SENT sid="5" pm="."><plain>Combined MC/SNP-A karyotyping lead to higher diagnostic yield of chromosomal defects (74% vs 44%, P &lt; .0001), compared with MC alone, often through detection of novel lesions in patients with <z:mpath ids='MPATH_458'>normal</z:mpath>/noninformative (54%) and abnormal (62%) MC results </plain></SENT>
<SENT sid="6" pm="."><plain>Newly detected SNP-A defects contributed to poorer prognosis for patients stratified by current morphologic and clinical risk schemes </plain></SENT>
<SENT sid="7" pm="."><plain>The presence and number of new SNP-A detected lesions are independent predictors of overall and event-free survival </plain></SENT>
<SENT sid="8" pm="."><plain>The significant diagnostic and prognostic contributions of SNP-A-detected defects in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and related diseases underscore the utility of SNP-A when combined with MC in <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> </plain></SENT>
</text></document>